G1 Therapeutics RALLY
Earnings/News
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
- Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
- GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
- FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.